Vertiflex completed a US $40MM financing round. Proceeds will support U.S. commercial expansion of the Superion® Indirect Decompression System, a minimally invasive implant for the treatment of moderate lumbar spinal stenosis.
New investors Endeavour Vision and H.I.G. BioHealth led the round with participation from existing investors, New Enterprise Associates, Thomas McNerney and Alta.
Superion received Premarket Approval from FDA in 2015 following completion of a randomized controlled trial, and as of January 2017, the system is described by a new American Medical Association CPT Category I code.
To accommodate growth, Vertiflex recently relocated corporate headquarters from San Clemente to a larger facility in Carlsbad, California with expanded distribution capability and a physician education center.
Vertiflex completed a US $40MM financing round. Proceeds will support U.S. commercial expansion of the Superion® Indirect Decompression System, a minimally invasive implant for the treatment of moderate lumbar spinal stenosis.
New investors Endeavour Vision and H.I.G. BioHealth led the round with participation from existing investors, New...
Vertiflex completed a US $40MM financing round. Proceeds will support U.S. commercial expansion of the Superion® Indirect Decompression System, a minimally invasive implant for the treatment of moderate lumbar spinal stenosis.
New investors Endeavour Vision and H.I.G. BioHealth led the round with participation from existing investors, New Enterprise Associates, Thomas McNerney and Alta.
Superion received Premarket Approval from FDA in 2015 following completion of a randomized controlled trial, and as of January 2017, the system is described by a new American Medical Association CPT Category I code.
To accommodate growth, Vertiflex recently relocated corporate headquarters from San Clemente to a larger facility in Carlsbad, California with expanded distribution capability and a physician education center.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
